- NSE
AstraZeneca Pharma India Limited
Healthcare ASTRAZEN
8711.50INR
82.00
(
0.95%)
Last update at
Day Range
52 Week Range
Fundamentals
- Previous Close 8629.50
- Market Cap 210752.59M
- Volume5,244
- P/E Ratio 105.80
- EBITDA 3141.20M
- Revenue TTM 20061.70M
- Revenue Per Share TTM 802.69
- Gross Profit TTM 8738.50M
- Diluted EPS TTM 79.57
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Financials
Income Statement
Balance Sheet
Change in Cash
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Income before tax | 1563.60M | 2195.40M | 1341.00M | 830.40M | 1270.90M |
| Net income | 1157.40M | 1615.10M | 992.90M | 616.00M | 933.00M |
| Total Revenue | 17162.90M | 12955.30M | 10029.70M | 8056.00M | 8085.60M |
| Gross Profit | 7532.80M | 6222.70M | 5777.10M | 4481.40M | 4780.20M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 15181.20M | 10780.30M | 9848.85M | 8565.60M | 7747.10M |
| Intangible assets | 6.60M | 21.10M | - | - | - |
| Other current assets | 561.70M | 299.60M | 266.18M | 187.45M | 154.04M |
| Deferred long term liab | - | - | - | - | - |
| Non current assets other | - | - | - | - | - |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Change in Cash | 305.70M | 52.30M | 519.21M | 960.80M | 2688.40M |
| Operating Cash | 653.60M | 278.70M | 582.98M | 1008.00M | 1047.80M |
| Free Cash Flow | 636.10M | 171.10M | 497.78M | 911.80M | 970.70M |
Peer Comparison
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change | Price | Market Cap (M) | P/E Ratio |
|---|---|---|---|---|
| ASTRAZEN AstraZeneca Pharma India Limited |
82.00 0.95% | 8711.50 | 210752.59 | 105.80 |
| SUNPHARMA Sun Pharmaceutical Industries Limited |
74.80 4.59% | 1702.70 | 4224508.76 | 40.32 |
| DIVISLAB Divi's Laboratories Limited |
260.50 4.38% | 6213.00 | 1752225.28 | 70.47 |
| TORNTPHARM Torrent Pharmaceuticals Limited |
52.30 1.31% | 4039.50 | 1362716.66 | 63.48 |
| CIPLA Cipla Limited |
9.90 0.75% | 1321.50 | 1183505.97 | 21.74 |
Profile
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
AstraZeneca Pharma India Limited
Manyata Embassy Business Park, Bengaluru, India, 560045
- 91 80 6774 8000
- https://www.astrazeneca.in
- Employees : 600
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Gagandeep Singh Bedi | MD, Country Pres & Exec. Director | 1971 |
| Mr. Rajesh Marwaha | CFO & Whole-Time Director | 1963 |
| Mr. Pratap Rudra Bhuvanagiri | Legal Counsel | NA |
| Ms. Manasa R. | Company Sec. & Compliance Officer | NA |
| Ms. Smita Saha | VP of HR | 1970 |
| Mr. Richard Cheeseman | Head of Engineering & Facilities | 1973 |
| Mr. Vimlesh Maheshwari | Fin. Controller | NA |
| Dr. K. R. Premnath Shenoy | Director of Regulatory | 1956 |
| Mr. Ramesh Kadaba Venkatapathi | Director of Quality Assurance & Technical Services | 1952 |
| Dr. Paurus Mehelli Irani | Global Medical Affairs Leader - Infection | 1967 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.